Suppr超能文献

[利用多基因检测(MGPT)诊断遗传性肿瘤——日本及全球的现状与问题]

[Diagnosis of Hereditary Tumors Using Multi Gene Panel Testing(MGPT)-Current Status and Issues in Japan or Worldwide].

作者信息

Hirasawa Akira

机构信息

Dept. of Clinical Genomic Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University.

出版信息

Gan To Kagaku Ryoho. 2024 Jul;51(7):677-680.

Abstract

Pathogenic variant carriers of hereditary tumors have the risk of developing cancer in multiple organs, and genetic testing can be used as an opportunity to conduct surveillance for early detection of cancer and to prevent the development of new cancers and it becomes possible to develop individualized preventive strategies including risk-reductive surgery. Multi gene panel testing(MGPT), which simultaneously measures several dozen to more than 100 genes, has been widely used to diagnose of hereditary tumors in worldwide since around 2014. Although, MGPTs has not been approved under the Pharmaceutical and Medical Devices Act in Japan. MGPTs for hereditary tumors can be expected to become the mainstream of diagnosis for hereditary tumors in near future.

摘要

遗传性肿瘤的致病基因变异携带者有多个器官发生癌症的风险,基因检测可作为开展监测以早期发现癌症、预防新癌症发生的契机,并且有可能制定包括降低风险手术在内的个性化预防策略。多基因panel检测(MGPT)可同时检测几十到100多个基因,自2014年左右以来已在全球广泛用于遗传性肿瘤的诊断。不过,MGPT在日本尚未根据《药品和医疗器械法》获得批准。遗传性肿瘤的MGPT有望在不久的将来成为遗传性肿瘤诊断的主流。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验